Alvine Pharmaceuticals Announces Upcoming Presentation of Phase 2a ALV003 Data in Patients with Celiac Disease
SAN CARLOS, CA., September 22, 2011 - Alvine Pharmaceuticals, Inc. today announced that data from its Phase 2a trial of ALV003 in patients with celiac disease will be presented at the 19th United European Gastroenterology Week (UEGW) in Stockholm. Details of the presentation follow:
Abstract #OP050B: “ALV003, A Novel Glutenase, Attenuates Gluten-Induced Small Intestinal Mucosal Injury in Celiac Disease Patients: A Randomized Controlled Phase 2A Clinical Trial”
Session Title: Free Paper Session: Late breaking news
Presentation Date/Time: Monday, October 24 at 2:12 to 2:24 p.m. CEST
Presenter: Markku Mäki, M.D., Ph.D., Chair and Professor of Pediatrics at the University of Tampere and Tampere University Hospital in Finland
Location: Hall K1/2
About Celiac Disease
Celiac disease is the most common hereditary autoimmune disease, affecting approximately 6 million people in the U.S. and E.U. Celiac disease is an acquired autoimmune disorder that develops in genetically susceptible individuals after exposure to dietary gluten, the difficult to digest protein found in wheat, rye and barley. It is a systemic illness that affects many organ systems, causing chronic gastrointestinal symptoms, such as nausea, diarrhea, and constipation, and can potentially cause serious medical consequences, including malabsorption, osteoporosis, anemia, infections, end-stage renal disease, malignancies and an increased mortality rate. Currently there is no approved therapy for celiac disease and the only treatment option for patients is to attempt to follow a strict, life-long gluten-free diet (GFD).
ALV003 is an orally administered mixture of two recombinant proteases engineered to degrade gluten into non-immunogenic peptide fragments, by targeting the glutamine and proline residues that are common in gluten. ALV003 consists of a cysteine protease (EP-B2) and a prolyl endopeptidase (PEP). ALV003 is being developed by Alvine as a potential treatment for patients with celiac disease and is currently in Phase 2 clinical development.
Alvine Pharmaceuticals, Inc. is a private clinical-stage specialty biopharmaceutical company located in San Carlos, Calif., focused on the development of innovative biologics targeting autoimmune and inflammatory diseases, including celiac disease. Alvine is focusing clinical development efforts on ALV003, an investigational drug in Phase 2 trials that could potentially be the first approved therapeutic treatment for patients with celiac disease. For additional information about the company, please visit http://www.alvinepharma.com.
Kirk Essenmacher M.D., M.B.A.
Vice President of Marketing, Corporate and Strategic Development
Phone: (650) 596-2434
Phone: (415) 946-1058